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INTRODUCTION 
Glucose intolerance (5,14), hyperinsulinemia, (3,9), insulin-
resistance (2,4) and hyperglucagonemia (12,17,18) are common in 
patients with advanced liver disease. Several hormonal abnor-
malities are reported in cirrothic patient and one thought to 
eighte~ contribute to or be responsible for the reduced plasma 
concentrations of the three principal branched chain acids (BCAA) 
valine, leucine and isoleucine that are characteristic of end-
stage liver disease. As' a result, these same hormonal abnor-
malities are thought also to contribute to the decreased molar 
ratio that exists in plasma between the BCAA and the aromatic 
amino acids (AAA) tyrosine, phenylalanine and tryptophan in cir-
rhotics (7,13,15,20). We report our observations concerning the 
plasma levels of insulin and glucagon and the major aminoacids 
before and after orthotopic liver transplantation (OLTx). The 
changes observed occur in cirrhotics postoperatively were compared 
to those observed to occur in a non-cirrhotic human recipient with 
normal liver function, who underwent liver transplantation for 
multiple hepatic adenomatosis and to those observed in five normal 
dogs which were submitted to liver replacement under controlled 
laboratory conditions. 
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MATERIAL AND METHODS 
Case Material 
The clinical characteristics of the eight cirrhotic patients 
and the single individual with multiple hepatic adenomatosis 
studied ere shown in Table l. As can be seen from the Table, 
patient with multiple hepatic adenomatosis had normal 
function. 
TABLE 1: PATIENTS TREATED WHITB OLTx 
NAME SEX AGE DIAGNOSIS BILIRUBIN PROTHROMBIN ALBUMIN 
(years) (mg/l00m1) Time (sec) (g/ll 
BR M IS Chronic active hepatitis 3S.S lS/13 2.7 
RY F 25 Chronic active hepatitis 9.9 15/13 2.6 
TH F 23 Chronic active hepatltis 2.2 16/13 2.2 
GH M 37 Sclerosing Cholangitis 19.7 15/13 2.6 
SJ F 41 Sclerosing Cholangitis 15.3 14.4/13 2.9 
KD M 34 Sclerosing Cholangitis 23.7 14/13 2.8 
SR F 29 Wilson's Disease 3.5 16.S/13 2.7 
SF F 43 1 Antitrypsin deficency 4.9 14/13 2.8 
FOR NEOPLASM 
GB F 29 Adenomatosis 0.5 13/13 3.0 
Clinical characteristics, bilirubin, prothrombin time and albumin 
levels of the eight cirrhotic patien~s and the single patient with 
multiple adenomatosis. 
the 
liver 
In contrast, the patients with liver disease all had moderately 
advanced liver disease as documented by the abnormalities in their 
blirubin, prothrombin time and albumin levels. 
Cyclosporine and prednisone were used as the immunodepressive 
agents for all of the recipients studied (21,22). 
The five mongrel dogs transplanted and studied weighted between 
15-20 kg and like the human studied, were given cyclosporine and 
prednisone to prevent rejection using doses that, on a mg per kg 
basis, were similar to those used by the patients (10). The surgi-
cal proc~dures used for the patients and animals was identical 
(10,22) . 
Special Analysis 
The plasma levels of immunoreactive insulin (IRI) were deter-
mined by radioimmunoassay using an insulin kit obtained from 
Serono Diagnostics (Braintree, MO). The detection limit of the as-
say was 5 U/ml. The plasma levels of C-peptide (CP) were deter-
mined by radioimmunoassay using a C-peptide kit obtained from 
Serono Diagnostics.The detection limit of the assay was 0.2 ng/ml. 
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The plasma levels of immunoreactive glucagon (IRG) were deter-
mined with a glucagon kit also obtained from Serono Diagnostics. 
This kit was chosen specifically because of its high degree of 
accuracy, precision and specificity as has been reported by Kenny 
et al (11). Samples for the glucagon assay were collected in 
chilled tubes containing 500 units of a trypsin inhibitor 
(aprotinin) and 1.2 mg of sodium EDTA/ml of whole blood collected 
for assay. 
The detection limit for the assay was 15 pg/ml. 
For representative blood samples obtained from each patient 
studied, both before and after transplantation, a gel filtration 
technique (1), was used to determine the amount of IRG-detectable 
glucagon having molecular weights of 3.500, 7.000 and 40.000 D . 
Insulin/glucagon molar rations were calculated as suggested by 
Muller (16) using the formula (IRI (uU/ml)/IRG (pg/ml) x 23.33 = 
Ratio. This formula assumes that insulin has a molecular weight of 
6.000 D and a biologic activity of 25 units/mg. It also assumes 
that glucagon has a molecular weight of 3,500 D. The addition of 
cyclosporine, to achieve concentration of the drug found in blood 
postoperatively, to samples of blood assayed for IRG, CP, and IRI, 
was found not to effect the assay results. 
Amino acid profiles were determined on deproteinized samples of 
plasma treated with 4% sulfosalicylic acid. The resultant super-
natants were applied to an amino acid analyzer (Beckman 
Instruments, Somerset, NJ) and the levels of free BCAA and AAA in-
cluding tryptophan were determined: The glucose determinations 
were made using a glucose-oxidase method (8). 
Statistical Analysis 
The unpaired Student's t-test was used for statistical analysis 
of the data. A p value <0.05 was considered to be significant. 
RESULTS 
End-Stage Liver Disease 
Glucagone, Insulin and C-peptide levels (Fig. LA). In the eight 
patients studied, the C-peptide plasma concentrations were allhigh 
normal preoperatively and rose 2 and 1/2-fold during the first 12 
hours following liver transplantation to a maximum level of 10 
ng/ml and remaining elevated for a least 30 days (Fig. lA). 
The plasma IRI levels followed a somewhat different pattern 
(Fig. LA). Following transplantation, there was a two-fold in-
crease in the IRI levels but this increase lasted only for a new 
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hours and subsequently returned to near normal levels at four days 
post-transplantation. 
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When studied at six months, both the insulin and C-peptide 
plasma levels were slightly elevated (Table 2). 
TABLE 2: LEVELS OF GLUCAGON, INSULIN, C-PEPTIDE AND IRI/IRG MOLAR RATIO 
NORMAL 
SUBJECTS 
CIRRHOTIC 
PATIENTS 
Before OLTx 
30 daYS 
ai'ter OLTx 
180 days 
after OLTx 
tpTAL , 
GLUCAGON 
(pg/ml) 
10, 90,!lS 
35O.!, 60 
P 0.05 
e ·750.=110 
p 0.01 
eo! 12 
n.s. 
M.IM. 3500 
GLUCAGON 
(pg/ml) 
75Z16 
294.!.51 
P 0.05 
638=.87 
p' 0.01 
68=.9 
n.s. 
INSULIN C-PEPTIDE IRI/IRG 
(uUIImll (ng/ml) 
25!.5 4 .::0.5 1. 5.!O. 5 
n.s. n.S. p 0,01 
22.:.8 6 .::1 O.6!,O.1 
• n.s. p 0.01 P 0.001 
30.:7.15 3.8!,O.5 10.2,:1 
p 0.05 n.s. p 0.001 
Levels of glucagon, C-peptlde. insulin Rnd IRIIIRG ratio in nOI',!,al subJects, and 
in 8 cirrhotic patients who underwent liver transplantation. The deterMinations 
in the operated patients were made before transplantation, 30 days and 180 days 
after transplantation. The data for "normal subjects" refer to deterMlnations 
obtuned 1n 10 healthy people age 18-45 years. Each value is express~d as M + S.D. 
Significance (p) 1n relation to the values of normal subjects. 
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Glucagon - Before operation, the plasma levels of IRG were four 
times the normal values (Table 2). After transplantation, the IRG 
level rose progressively. The highest mean plasma levels of IRG 
were found at 30 days following transplantation (Fig. lA), but 
when restudied at 6 months had returned to the normal range (table 
2). The resultant IRI/IRG molar ratio was decreased significantly 
as a consequence of the observed hyperglucagonemia with near nor-
mal insulin levels observed after the first 4 post-transplant 
days. 
The gel filtration studies demonstrated that the 
hyperglucagonemia, both before and after transplantation, was 
predominantly due to the presence of IRG having a molecular weight 
of 3,500 D. This form of the hormone is thought to be the most 
biologically active fraction 
glucose levels was observed 
glucocorticoid therapy used 
(6). A sharp increase of plasma 
probably related to the intense 
during the first days following 
transplantation. Blood glucose levels-returned to the normal range 
6 days after operation and remained normal during all of the ob-
servation period (data not reported). 
Amino Acids - The preoperative elevations of AAA (Fig. IB) and 
the depressed levIes of BCAA (Fig. IB) returned to the normal 
range for each within 12 hours after transpalntation. More 
importantly, the plasma amino acid levels and the BCAA/AAA ratio 
(Fig. IB) subsequently achieved the normal range for the entire 
3D-day study period. 
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Control study - No changes were observed in the normal levels 
of IRI, IRG and the plasma amino acid levels following liver 
transplantation in the one patient with multiple hepatic 
adenomatosis studied (Fig. 2A). Similarly, no changes were ob-
served for these same substances in the five normal dogs submitted 
to liver transplantation (Fig. 2B). However, this individual and 
these dogs had no abnormalities preoperatively that might other-
wise heve been expected to correct following successful 
transplantation. Importantly these data suggest that neighter the 
doses of prednisone used nor the cyclosporine used to prevent 
rejection contributed to the hormonal and amino acid finding ob-
served in the cirrhotic patients studied. 
DISCUSSION 
The purpose of this study was to determine if the hormonal ab-
normalities which are characteristic of end-stage chronic liver 
disease can be corrected by orthopic liver transplantation. 
Both the hyperinsulinemia and the hyperglucagonemia evident 
preoperatively persisted for some time after successful transplan-
tation suggesting that the hypersecretion of these two hormones 
which characterizes chronic liver disease was not promptly co'r-
rected with elimination of the liver disease per see Although the 
plasma insulin level gradually returned to the normal range within 
days of the transplant procedure, the plasma glucagon level con 
tinued to be abnormally elevate and in fact became progressively 
more abnormal (more elevated) for several weeks before it also be-
came normal sometime between 1 and 6 months postoperatively. These 
data coupled with the data obtained from a patient with multiple 
hepatic adenoma but normal liver function suggest that the abnor-
malities seen in the patients with advanced liver disease 
reflected alterations in hormone balance and energy metabolism 
which were due to the individual's advanced liver disease and not 
to the surgical procedure and the immunotherapy that follow the 
procedure. These observations also support the prior findings of 
Sherwin (17, 18) and others (6) that suggest that over production 
of the pancreatic hormones rather than defective hepatic uptake 
accounts for the nyperglucagonemia and hyperinsulinemia of ad-
vanced liver disease. Even more importantly, the failure to 
demonstrate any relationship between the changes in the plasma 
levels of glucagon and either the BCAA or AAA in these studies 
suggests that the abnormal plasma levels of both classes 'of amino 
acid present in patients with liver disease are not regulated or 
determined to a major degree by the hyperglucagonemia present in 
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patients with advanced liver disease. Conversely, these data sug-
gest strongly that the elevated plasma level of glucagon seen in 
advanced liver disease plays little important role in the produc-
tion or maintenance of the abnormal plasma amino acid levels seen 
in patients with advanced liver disease. 
In contrast to the observatios of plasma glucagon, plasma in-
sulin levels returned to near normal range within days of the 
transplant procedure despite apparent persistent hypersecretionof 
the hormone documented by the increased plasma level of C-peptide 
and a progressive rise in the C-peptide/insulin ratio. This ap-
parent increase in insulin secretion was independent of the tran-
sient increase of glucose observed during the first 6 days after 
transplantation, and is well beyond the period of increased blood 
glucose seen postoperatively. These data suggest that the 
transplanted liver actively removes secreted insulin from the por-
tal circulation, thereby maintaining a normal systemic plasma 
level of the hormone despite excess production and secretion of 
the hormone by the pancreas. Moreover, as the renal function of 
the patients and the animals studied did not become impaired (data 
not shown), it is most unlikily that these changes reflect an al-
teration in renal handling or clearance of eighter C-peptide or 
insulin. None the less, it is at least theoretically possible that 
the increased C-peptide levels reflect cyclosporine nephrotoxicity 
not apparent from the serial creatinine or BUN determinations made 
throughout the study. 
The changes in the plasma levels of insulin and glucagon seen 
in the eight patients with advanced chronic liver disease who were 
studied were not seen in the one patient with normal hepatic func-
tion and multiple hepatic adenomatosis studied or in the five nor-
mal dogs that were trasplanted experimentally. Thus the hormonal 
changes observed in the patients with advanced liver disease would 
appear to be specific for liver disease per se and not the 
tranplant procedure or the immunodepressive regimen used. 
These data are consistent with the recent suggestion that the 
reduced branched chain amino acid levels seen in cases of advance 
cirrhosis are due to the increased plasma levels of insulin seen 
in such individuals. It has been proposed by the authors of these 
latter hypotesis that the systemic hyperinsulinemia of advanced 
chronic liver disease drives plasma ~CAA into adipocytes, thereby 
producing an abnormal reduction in the plasma level of the 
branched chain amino acid which is characteristic of cirrhosis 
(19). The current observations that the plasma levels of the 
branched chain amino acids normalize concurrently with the plasma 
levels of insulin provides strong, albeit indirect, support for 
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the hypothesis. 
Equally important, however, is the observation that the plasma 
level of branched chain amino acids normalize while the plasma 
glucagon level becomes progressively more abnormal. This suggests 
quite strongly that the plasma level of glucagon does not impor-
tantly regulate the plasma level of the brancheG chain amino 
acids. 
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